NO2686520T3 - - Google Patents

Info

Publication number: NO2686520T3
Authority: NO; Norway

Application number

NO12759983A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-06

Filing date

2012-03-05

Publication date

2018-03-17

2012-03-05 Application filed filed Critical

2018-03-17 Publication of NO2686520T3 publication Critical patent/NO2686520T3/no

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Materials Engineering (AREA)
Inorganic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Enzymes And Modification Thereof (AREA)
Curing Cements, Concrete, And Artificial Stone (AREA)

NO12759983A 2011-06-06 2012-03-05 NO2686520T3 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161493536P	2011-06-06	2011-06-06

Publications (1)

Publication Number	Publication Date
NO2686520T3 true NO2686520T3 (fr)	2018-03-17

Family

ID=47262177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO12759983A NO2686520T3 (fr)	2011-06-06	2012-03-05

Country Status (23)

Country	Link
US (6)	US9145366B2 (fr)
EP (5)	EP4026829A1 (fr)
JP (6)	JP6290781B2 (fr)
KR (5)	KR102000485B1 (fr)
CN (1)	CN106518759B (fr)
AU (4)	AU2012268426B2 (fr)
CA (2)	CA3135440A1 (fr)
CY (4)	CY1117177T1 (fr)
DK (4)	DK3000808T3 (fr)
ES (4)	ES2900572T3 (fr)
HR (4)	HRP20211916T1 (fr)
HU (4)	HUE057571T2 (fr)
IL (1)	IL229775A (fr)
LT (3)	LT3290404T (fr)
MX (2)	MX337216B (fr)
NO (1)	NO2686520T3 (fr)
PL (4)	PL3290404T3 (fr)
PT (4)	PT3683209T (fr)
RS (3)	RS56580B1 (fr)
RU (2)	RU2764667C2 (fr)
SI (4)	SI2718265T1 (fr)
SM (3)	SMT202000061T1 (fr)
WO (1)	WO2012170377A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2327696A1 (fr)	2006-06-26	2011-06-01	Warner Chilcott Company, LLC	Inhibiteurs de la prolyl hydroxylase et procédés d'utilisation
NO2686520T3 (fr)	2011-06-06	2018-03-17
SG11201509998WA (en) *	2013-06-13	2016-01-28	Akebia Therapeutics Inc	Compositions and methods for treating anemia
AR099354A1 (es)	2013-11-15	2016-07-20	Akebia Therapeutics Inc	Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
ES2898476T3 (es)	2014-09-02	2022-03-07	Sunshine Lake Pharma Co Ltd	Compuesto de quinolona y uso del mismo
CN107427503A (zh)	2015-01-23	2017-12-01	阿克比治疗有限公司	2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
WO2016153996A1 (fr) *	2015-03-20	2016-09-29	Akebia Therapeutics, Inc.	Inhibiteurs de l'enzyme prolyl hydroxylase du facteur inductible par hypoxie enrichis en deutérium
CN106146395B (zh)	2015-03-27	2019-01-01	沈阳三生制药有限责任公司	3-羟基吡啶化合物、其制备方法及其制药用途
TWI836883B (zh)	2015-04-01	2024-03-21	美商阿克比治療有限公司	用於治療貧血之組合物及方法
CN110088088B (zh) *	2016-12-13	2022-03-29	苏州科睿思制药有限公司	{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
IL269623B2 (en) *	2017-03-29	2025-05-01	Emerald Health Pharmaceuticals Inc	Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
WO2019028150A1 (fr)	2017-08-01	2019-02-07	Akebia Therapeutics, Inc.	Compositions destinées à être utilisées dans des méthodes de traitement des hémoglobinopathies
CA3097219A1 (fr) *	2018-05-09	2019-11-14	Akebia Therapeutics, Inc.	Procede de preparation d'acide 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino]acetique
WO2020075199A1 (fr)	2018-10-12	2020-04-16	Mylan Laboratories Limited	Formes polymorphes de vadadustat
WO2020108941A1 (fr)	2018-11-28	2020-06-04	Sandoz Ag	Cristaux à plusieurs composants d'un inhibiteur de hif prolyl hydroxylase disponible par voie orale
US12134600B2 (en)	2019-04-26	2024-11-05	Kaneka Corporation	Method for producing a vadadustat intermediate
US11524939B2 (en)	2019-11-13	2022-12-13	Akebia Therapeutics, Inc.	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111087343B (zh) *	2019-11-29	2022-02-18	万华化学集团股份有限公司	一种羟基吡啶配体及其制备方法和催化应用
US20230159462A1 (en) *	2019-12-10	2023-05-25	Akebia Therapeutics, Inc.	Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
EP4094832A4 (fr)	2020-01-24	2024-04-17	APS Japan Co., Ltd.	Unité de photocatalyseur et masque pourvu d'une unité de photocatalyseur
WO2022006427A1 (fr) *	2020-07-02	2022-01-06	Akebia Therapeutics, Inc.	Processus de fabrication de 3,5-dichloropicolinonitrile pour la synthèse de vadadustat
GB202011431D0 (en) *	2020-07-23	2020-09-09	Johnson Matthey Plc	Polymorphs of vadadustat and methods for preparing the polymorphs
CN118715015A (zh)	2021-12-17	2024-09-27	阿克比治疗有限公司	选择性phd1抑制剂化合物、组合物和使用方法
EP4661861A1 (fr)	2023-02-06	2025-12-17	Institut National de la Santé et de la Recherche Médicale	Utilisation d'agents de stabilisation de hif-1a pour le traitement d'interféronopathies de type i

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3655679A (en) *	1969-06-25	1972-04-11	Merck & Co Inc	Certain aryl pyridine carboxylic acid derivatives
US3703582A (en)	1970-04-20	1972-11-21	Merck & Co Inc	Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en)	1971-12-21	1975-07-15	Sagami Chem Res	Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en)	1972-07-17	1977-04-05	Boehringer Ingelheim Gmbh	Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (fr)	1990-02-26	1994-02-01	Lilly Co Eli
US5405613A (en)	1991-12-11	1995-04-11	Creative Nutrition Canada Corp.	Vitamin/mineral composition
TW352384B (en)	1992-03-24	1999-02-11	Hoechst Ag	Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de)	1992-06-11	1993-12-16	Thomae Gmbh Dr K	Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0650961B1 (fr)	1993-11-02	1997-03-05	Hoechst Aktiengesellschaft	Amides d'acide carboxylique hétérocycliques substitués, leur preparation et leur utilisation comme médicaments
DK0650960T3 (da)	1993-11-02	1997-09-01	Hoechst Ag	Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
TW406076B (en)	1993-12-30	2000-09-21	Hoechst Ag	Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1 (de)	1994-03-25	1995-09-28	Hoechst Ag	Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de)	1994-03-25	1995-09-28	Hoechst Ag	Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en)	1995-01-20	1998-08-04	Cornell Research Foundation, Inc.	Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en)	1995-09-28	2002-12-01	Hoechst Ag	Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja)	1995-12-15	1997-08-26	Otsuka Pharmaceut Co Ltd	医薬組成物
CA2253282A1 (fr)	1996-04-30	1997-11-06	Hoechst Aktiengesellschaft	Esters d'amide de 3-alcoxypyridine-2-acide carboxylique, leur preparation et leur utilisation comme medicaments
DE19620041A1 (de)	1996-05-17	1998-01-29	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de)	1996-12-04	1998-06-10	Hoechst Ag	3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1282319A (zh)	1997-10-09	2001-01-31	小野药品工业株式会社	氨基丁酸衍生物
DE19746287A1 (de)	1997-10-20	1999-04-22	Hoechst Marion Roussel De Gmbh	Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1297440A (zh)	1998-03-23	2001-05-30	阿温蒂斯药物制品公司	哌啶基和n－脒基哌啶基衍生物
US6159379A (en)	1999-05-04	2000-12-12	Baker Hughes Incorporated	Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja)	1999-08-05	2001-02-20	Yamanouchi Pharmaceut Co Ltd	三環式ヘテロアリール誘導体
US6589758B1 (en)	2000-05-19	2003-07-08	Amgen Inc.	Crystal of a kinase-ligand complex and methods of use
US6849718B2 (en)	2001-03-20	2005-02-01	Dana Farber Cancer Institute, Inc.	Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en)	2001-03-20	2005-02-15	Dana Farber Cancer Institute, Inc.	Pharmaceuticals and methods for treating hypoxia and screening methods therefor
AU2002241154A1 (en)	2001-03-21	2002-10-03	Isis Innovation Ltd.	Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0 (sv)	2001-04-12	2001-04-12	Astrazeneca Ab	New crystalline forms
US6566088B1 (en)	2001-10-04	2003-05-20	Board Of Regents, The University Of Texas System	Prolyl-4-hydroxylases
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
CN102552262A (zh)	2001-12-06	2012-07-11	法布罗根股份有限公司	提高内源性红细胞生成素(epo)的方法
IL165258A0 (en)	2002-05-17	2005-12-18	Celgene Corp	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
IL166426A0 (en)	2002-08-29	2006-01-15	Merck & Co Inc	N-biarylmethyl aminocycloalkanecarboxamide derivatives
PL376770A1 (pl)	2002-10-16	2006-01-09	Isis Innovation Limited	Hydroksylazy asparaginylowe i ich modulatory
CA2506799A1 (fr)	2002-11-21	2004-06-10	Eli Lilly And Company	Modulateurs de la kinase a lignee evolutive mixte
US7618940B2 (en)	2002-12-06	2009-11-17	Fibrogen, Inc.	Fat regulation
US8124582B2 (en)	2002-12-06	2012-02-28	Fibrogen, Inc.	Treatment of diabetes
US7183287B2 (en)	2003-04-03	2007-02-27	Pharmacia Corporation	Substituted pyrimidinones
US20060251638A1 (en)	2003-06-06	2006-11-09	Volkmar Guenzler-Pukall	Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en)	2003-06-06	2013-12-24	Fibrogen, Inc.	Enhanced erythropoiesis and iron metabolism
US7323475B2 (en)	2003-06-06	2008-01-29	Fibrogen, Inc.	Nitrogen-containing heteroaryl compounds and methods of use thereof
GB0314129D0 (en)	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
JPWO2005108370A1 (ja)	2004-04-16	2008-03-21	味の素株式会社	ベンゼン化合物
NZ551632A (en)	2004-05-28	2009-09-25	Fibrogen Inc	HIF prolyl hydroxylase activity assay
EP1771418A2 (fr)	2004-05-31	2007-04-11	Tanabe Seiyaku Co., Ltd.	Agent d'ouverture de canaux k actives par le calcium a conductance elevee
AU2005275181A1 (en)	2004-07-14	2006-02-23	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
TW200616969A (en)	2004-09-17	2006-06-01	Tanabe Seiyaku Co	Imidazole compound
US20080213404A1 (en)	2005-02-04	2008-09-04	Johnson Randall S	Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (de)	2005-04-28	2006-11-09	Bayer Healthcare Ag	Dipyridyl-dihydropyrazolone und ihre Verwendung
CN101394843A (zh)	2005-06-06	2009-03-25	菲布罗根公司	使用HIFα稳定剂的改进的贫血治疗
ATE470439T1 (de)	2005-06-15	2010-06-15	Fibrogen Inc	Verwendung von hif 1alfa modulatoren zur behandlung von krebs
WO2007033216A2 (fr)	2005-09-12	2007-03-22	Beth Israel Deaconess Medical Center	Procedes et compositions pour le traitement et le diagnostic de maladies caracterisees par la fuite vasculaire, l'hypotension, ou un etat procoagulant
WO2007038571A2 (fr)	2005-09-26	2007-04-05	Smithkline Beecham Corporation	Antagonistes de la prolyl-hydroxylase
US20090176726A1 (en)	2005-10-11	2009-07-09	Fisher David E	Methods for treating mitf-related disorders
AU2006326662B2 (en)	2005-12-09	2011-07-28	Amgen Inc.	Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
JP2009522383A (ja)	2006-01-09	2009-06-11	ビーティージー・インターナショナル・リミテッド	低酸素誘導因子−１の調節物質及び関連する使用
EP1983823A1 (fr)	2006-01-17	2008-10-29	VIB vzw	Inhibiteurs de la prolyl-hydroxylase 1 pour le traitement de la degenerescence des muscles du squelette
JP4801451B2 (ja)	2006-01-19	2011-10-26	株式会社日立ハイテクノロジーズ	走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
JP2009523812A (ja)	2006-01-19	2009-06-25	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	融合へテロ二環式キナーゼ阻害剤
ITMI20060179A1 (it)	2006-02-02	2007-08-03	Abiogen Pharma Spa	Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US7625927B2 (en)	2006-02-27	2009-12-01	Alcon Research, Ltd.	Method of treating glaucoma
US7588924B2 (en)	2006-03-07	2009-09-15	Procter & Gamble Company	Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
TW200808793A (en)	2006-03-07	2008-02-16	Smithkline Beecham Corp	Prolyl hydroxylase inhibitors
WO2007136990A2 (fr)	2006-05-16	2007-11-29	Smithkline Beecham Corporation	Inhibiteurs de prolyl hydroxylase
TWI394747B (zh)	2006-06-23	2013-05-01	Smithkline Beecham Corp	脯胺醯基羥化酶抑制劑
EP2327696A1 (fr)	2006-06-26	2011-06-01	Warner Chilcott Company, LLC	Inhibiteurs de la prolyl hydroxylase et procédés d'utilisation
CL2008000065A1 (es)	2007-01-12	2008-09-22	Smithkline Beecham Corp	Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
TW200845991A (en)	2007-01-12	2008-12-01	Smithkline Beecham Corp	N-substituted glycine derivatives: hydroxylase inhibitors
ES2446418T3 (es)	2007-04-18	2014-03-07	Amgen, Inc	Derivados de indanona que inhiben la prolil hidroxilasa
JP2010524935A (ja)	2007-04-18	2010-07-22	メルク・シャープ・エンド・ドーム・コーポレイション	新規１，８−ナフチリジン化合物
CA2685216C (fr)	2007-05-04	2014-07-08	Amgen Inc.	Derives de la thienopyridine et de la thiazolopyridine qui inhibent l'activite prolyle hydroxylase
CA2685942A1 (fr)	2007-05-16	2008-11-27	Merck & Co., Inc.	Spiroindalones
JP5702138B2 (ja)	2007-05-18	2015-04-15	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	過剰増殖障害および血管新生に関連する疾患の処置に有用なヘテロアリール置換ピラゾール誘導体
US8268794B2 (en)	2007-08-06	2012-09-18	Senju Pharmaceutical Co., Ltd.	Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
TW200908984A (en)	2007-08-07	2009-03-01	Piramal Life Sciences Ltd	Pyridyl derivatives, their preparation and use
JP2010535855A (ja)	2007-08-10	2010-11-25	クリスタルゲノミクス、インク．	ピリジン誘導体およびその使用方法
WO2009035534A2 (fr)	2007-09-07	2009-03-19	The Cleveland Clinic Foundation	Traitement d'une maladie ischémique de l'œil par activation pharmaceutique systématique d'un facteur induit par l'hypoxie (hif)
WO2009039321A1 (fr)	2007-09-19	2009-03-26	Smithkline Beecham Corporation	Inhibiteurs de la prolyl hydroxylase
WO2009039323A1 (fr)	2007-09-19	2009-03-26	Smithkline Beecham Corporation	Inhibiteurs de la prolyl hydroxylase
WO2009043093A1 (fr)	2007-10-04	2009-04-09	Newsouth Innovations Pty Limited	Inhibition de hif
WO2009049112A1 (fr)	2007-10-10	2009-04-16	Smithkline Beecham Corporation	Inhibiteurs de la prolyl hydroxylase
WO2009067790A1 (fr)	2007-11-26	2009-06-04	Uti Limited Partnership	STIMULATION DU FACTEUR 1α INDUCTIBLE PAR L'HYPOXIE (HIF-1α) POUR LE TRAITEMENT DE LA MALADIE ASSOCIÉE À CLOSTRIDIUM DIFFICILE (MACD), POUR LA MOTILITÉ INTESTINALE ET POUR DÉTECTER UNE INFECTION
WO2009073497A2 (fr)	2007-11-30	2009-06-11	Smithkline Beecham Corporation	Inhibiteurs des prolyl hydroxylases
WO2009070644A1 (fr)	2007-11-30	2009-06-04	Smithkline Beecham Corporation	Inhibiteurs de prolyl hydroxylases
WO2009073669A1 (fr)	2007-12-03	2009-06-11	Fibrogen, Inc.	Dérivés d'isoxazolopyridine destinés à être utilisés dans le traitement d'états à médiation par hif
JP2011507894A (ja)	2007-12-19	2011-03-10	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	プロリルヒドロキシラーゼ阻害剤
WO2009086592A1 (fr)	2008-01-04	2009-07-16	Garvan Institute Of Medical Research	Procédé d'augmentation du métabolisme
US8952160B2 (en)	2008-01-11	2015-02-10	Fibrogen, Inc.	Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
PT2268618E (pt) *	2008-03-03	2015-10-12	Novartis Ag	Compostos e composições moduladores da actividade tlr
US20090228298A1 (en) *	2008-03-04	2009-09-10	The General Electric Company	System and method of morphology feature analysis of physiological data
WO2009117676A2 (fr) *	2008-03-20	2009-09-24	Forest Laboratories Holdings Limited	Nouveaux dérivés de pipéridine servant d'inhibiteurs de stéaroyle-coa-désaturase
AR071997A1 (es)	2008-06-04	2010-07-28	Bristol Myers Squibb Co	Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
PE20110409A1 (es) *	2008-07-23	2011-06-22	Hoffmann La Roche	Compuestos heterociclicos antiviricos
BRPI0913485A2 (pt)	2008-09-15	2016-06-07	Kasina Laila Innova Pharmaceuticals Private Ltd	medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
JP5649584B2 (ja)	2008-11-14	2015-01-07	フィブロジェンインコーポレイテッド	Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
AU2010231615B2 (en) *	2009-03-31	2014-05-15	Kissei Pharmaceutical Co., Ltd.	Indolizine derivative and use thereof for medical purposes
WO2011057121A1 (fr)	2009-11-06	2011-05-12	Akebia Therapeutics Inc.	Compositions et méthodes pour traiter la colite
KR101652606B1 (ko) *	2011-06-06	2016-08-30	아케비아 테라퓨틱스 인코포레이티드	암 치료 방법으로서 저산소증 유도 인자-2 알파를 안정화시키기 위한 화합물 및 조성물
NO2686520T3 (fr)	2011-06-06	2018-03-17
WO2012174256A2 (fr)	2011-06-17	2012-12-20	The Regents Of The University Of Michigan	Profils de méthylation de l'adn dans le cancer
CN104024227B8 (zh)	2011-07-22	2025-07-29	北京贝美拓新药研发有限公司	抑制脯氨酸羟化酶活性的化合物的晶型及其应用
KR20160061911A (ko)	2013-04-08	2016-06-01	데니스 엠. 브라운	최적하 투여된 화학 화합물의 치료 효과
SG11201509998WA (en)	2013-06-13	2016-01-28	Akebia Therapeutics Inc	Compositions and methods for treating anemia
HK1223508A1 (zh)	2013-08-16	2017-08-04	Ohio State Innovation Foundation	用於調節dna甲基化的組合物和方法用於調節dna甲基化的組合物和方法
AR099354A1 (es)	2013-11-15	2016-07-20	Akebia Therapeutics Inc	Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2015112831A1 (fr)	2014-01-23	2015-07-30	Akebia Therapeutics, Inc.	Compositions et méthodes de traitement de maladies oculaires
CN107427503A (zh)	2015-01-23	2017-12-01	阿克比治疗有限公司	2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
WO2016153996A1 (fr)	2015-03-20	2016-09-29	Akebia Therapeutics, Inc.	Inhibiteurs de l'enzyme prolyl hydroxylase du facteur inductible par hypoxie enrichis en deutérium
TWI836883B (zh)	2015-04-01	2024-03-21	美商阿克比治療有限公司	用於治療貧血之組合物及方法
CA3097219A1 (fr)	2018-05-09	2019-11-14	Akebia Therapeutics, Inc.	Procede de preparation d'acide 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino]acetique

2012
- 2012-03-05 NO NO12759983A patent/NO2686520T3/no unknown
- 2012-06-05 PL PL17191362T patent/PL3290404T3/pl unknown
- 2012-06-05 JP JP2014514536A patent/JP6290781B2/ja active Active
- 2012-06-05 HU HUE19214405A patent/HUE057571T2/hu unknown
- 2012-06-05 KR KR1020147000297A patent/KR102000485B1/ko active Active
- 2012-06-05 EP EP21206374.7A patent/EP4026829A1/fr active Pending
- 2012-06-05 PT PT192144053T patent/PT3683209T/pt unknown
- 2012-06-05 RU RU2016139352A patent/RU2764667C2/ru active
- 2012-06-05 US US13/488,554 patent/US9145366B2/en active Active
- 2012-06-05 EP EP19214405.3A patent/EP3683209B1/fr active Active
- 2012-06-05 SI SI201230432T patent/SI2718265T1/sl unknown
- 2012-06-05 DK DK15189822.8T patent/DK3000808T3/da active
- 2012-06-05 SM SM20200061T patent/SMT202000061T1/it unknown
- 2012-06-05 CA CA3135440A patent/CA3135440A1/fr active Pending
- 2012-06-05 SM SM20170534T patent/SMT201700534T1/it unknown
- 2012-06-05 CA CA2838194A patent/CA2838194C/fr active Active
- 2012-06-05 RS RS20171181A patent/RS56580B1/sr unknown
- 2012-06-05 KR KR1020197007633A patent/KR102032864B1/ko active Active
- 2012-06-05 LT LTEP17191362.7T patent/LT3290404T/lt unknown
- 2012-06-05 DK DK12796374.2T patent/DK2718265T3/en active
- 2012-06-05 LT LTEP15189822.8T patent/LT3000808T/lt unknown
- 2012-06-05 PT PT151898228T patent/PT3000808T/pt unknown
- 2012-06-05 ES ES19214405T patent/ES2900572T3/es active Active
- 2012-06-05 PT PT171913627T patent/PT3290404T/pt unknown
- 2012-06-05 HR HRP20211916TT patent/HRP20211916T1/hr unknown
- 2012-06-05 RS RS20160013A patent/RS54517B1/sr unknown
- 2012-06-05 EP EP15189822.8A patent/EP3000808B1/fr active Active
- 2012-06-05 SI SI201231114T patent/SI3000808T1/en unknown
- 2012-06-05 RS RS20200130A patent/RS59902B1/sr unknown
- 2012-06-05 HU HUE15189822A patent/HUE034975T2/en unknown
- 2012-06-05 HR HRP20151416T patent/HRP20151416T1/hr unknown
- 2012-06-05 HU HUE12796374A patent/HUE026096T2/en unknown
- 2012-06-05 ES ES15189822.8T patent/ES2647602T3/es active Active
- 2012-06-05 PL PL15189822T patent/PL3000808T3/pl unknown
- 2012-06-05 PT PT127963742T patent/PT2718265E/pt unknown
- 2012-06-05 KR KR1020197007630A patent/KR102059366B1/ko active Active
- 2012-06-05 SI SI201231729T patent/SI3290404T1/sl unknown
- 2012-06-05 DK DK17191362.7T patent/DK3290404T3/da active
- 2012-06-05 PL PL12796374T patent/PL2718265T3/pl unknown
- 2012-06-05 CN CN201610967348.7A patent/CN106518759B/zh active Active
- 2012-06-05 KR KR1020207029586A patent/KR102293016B1/ko active Active
- 2012-06-05 PL PL19214405T patent/PL3683209T3/pl unknown
- 2012-06-05 EP EP17191362.7A patent/EP3290404B1/fr active Active
- 2012-06-05 WO PCT/US2012/040833 patent/WO2012170377A1/fr not_active Ceased
- 2012-06-05 MX MX2013014228A patent/MX337216B/es active IP Right Grant
- 2012-06-05 DK DK19214405.3T patent/DK3683209T3/da active
- 2012-06-05 ES ES17191362T patent/ES2771232T3/es active Active
- 2012-06-05 SI SI201231969T patent/SI3683209T1/sl unknown
- 2012-06-05 AU AU2012268426A patent/AU2012268426B2/en active Active
- 2012-06-05 MX MX2015016579A patent/MX347709B/es unknown
- 2012-06-05 RU RU2013158640/04A patent/RU2602083C2/ru active
- 2012-06-05 EP EP12796374.2A patent/EP2718265B1/fr active Active
- 2012-06-05 ES ES12796374.2T patent/ES2559850T3/es active Active
- 2012-06-05 LT LTEP19214405.3T patent/LT3683209T/lt unknown
- 2012-06-05 HU HUE17191362A patent/HUE048044T2/hu unknown
- 2012-06-05 KR KR1020197037296A patent/KR102171315B1/ko active Active
2013
- 2013-12-03 IL IL229775A patent/IL229775A/en active IP Right Grant
2015
- 2015-08-24 US US14/833,222 patent/US9776969B2/en active Active
2016
- 2016-01-14 CY CY20161100037T patent/CY1117177T1/el unknown
- 2016-01-15 SM SM201600013T patent/SMT201600013B/it unknown
2017
- 2017-04-12 AU AU2017202414A patent/AU2017202414B2/en active Active
- 2017-08-31 US US15/692,255 patent/US10246416B2/en active Active
- 2017-11-13 HR HRP20171740TT patent/HRP20171740T1/hr unknown
- 2017-11-15 CY CY20171101202T patent/CY1119605T1/el unknown
2018
- 2018-02-08 JP JP2018020595A patent/JP6510094B2/ja active Active
- 2018-10-15 AU AU2018250355A patent/AU2018250355B2/en active Active
2019
- 2019-03-13 US US16/352,705 patent/US10738010B2/en active Active
- 2019-04-03 JP JP2019070979A patent/JP6816195B2/ja active Active
2020
- 2020-02-03 CY CY20201100087T patent/CY1122639T1/el unknown
- 2020-02-06 HR HRP20200197TT patent/HRP20200197T1/hr unknown
- 2020-07-06 US US16/921,273 patent/US11267785B2/en active Active
- 2020-07-07 AU AU2020204528A patent/AU2020204528B2/en active Active
- 2020-12-23 JP JP2020213442A patent/JP7039682B2/ja active Active
2021
- 2021-12-08 CY CY20211101079T patent/CY1124874T1/el unknown
2022
- 2022-01-31 US US17/589,118 patent/US20230002323A1/en active Pending
- 2022-03-09 JP JP2022035813A patent/JP7284309B2/ja active Active
2023
- 2023-05-18 JP JP2023081959A patent/JP7685552B2/ja active Active

Also Published As

Publication number	Publication date
CN106518759A (zh)	2017-03-22
JP2018111697A (ja)	2018-07-19
KR20190032617A (ko)	2019-03-27
EP3683209A1 (fr)	2020-07-22
CN106518759B (zh)	2019-07-30
AU2018250355B2 (en)	2020-04-09
ES2647602T3 (es)	2017-12-22
HUE048044T2 (hu)	2020-05-28
US20190375713A1 (en)	2019-12-12
RU2016139352A3 (fr)	2020-01-27
PT2718265E (pt)	2016-02-15
NZ618570A (en)	2015-07-31
WO2012170377A1 (fr)	2012-12-13
LT3290404T (lt)	2020-02-25
HUE034975T2 (en)	2018-05-02
KR20190031593A (ko)	2019-03-26
PT3000808T (pt)	2017-11-23
ES2900572T3 (es)	2022-03-17
DK3683209T3 (da)	2021-12-06
KR20140037192A (ko)	2014-03-26
RS54517B1 (sr)	2016-06-30
RS59902B1 (sr)	2020-03-31
US9145366B2 (en)	2015-09-29
KR20200121911A (ko)	2020-10-26
KR102032864B1 (ko)	2019-10-16
HRP20171740T1 (hr)	2018-03-09
US9776969B2 (en)	2017-10-03
AU2020204528B2 (en)	2022-07-14
JP6816195B2 (ja)	2021-01-20
MX337216B (es)	2016-02-18
PL3290404T3 (pl)	2020-06-01
SMT201600013B (it)	2016-02-25
JP6510094B2 (ja)	2019-05-08
US20150361043A1 (en)	2015-12-17
KR102059366B1 (ko)	2019-12-26
AU2020204528A1 (en)	2020-07-30
EP3290404A1 (fr)	2018-03-07
KR102000485B1 (ko)	2019-07-16
JP2014522409A (ja)	2014-09-04
JP7685552B2 (ja)	2025-05-29
MX2013014228A (es)	2014-03-26
US10738010B2 (en)	2020-08-11
AU2012268426B2 (en)	2017-02-16
JP7284309B2 (ja)	2023-05-30
CY1117177T1 (el)	2017-04-05
JP2023103414A (ja)	2023-07-26
RS56580B1 (sr)	2018-02-28
RU2602083C2 (ru)	2016-11-10
HRP20211916T1 (hr)	2022-03-18
EP2718265B1 (fr)	2015-12-16
EP3683209B1 (fr)	2021-11-10
JP6290781B2 (ja)	2018-03-07
SMT201700534T1 (it)	2018-01-11
LT3000808T (lt)	2018-01-25
EP3000808B1 (fr)	2017-09-27
SI3000808T1 (en)	2018-02-28
SMT202000061T1 (it)	2020-03-13
CN103717575A (zh)	2014-04-09
EP2718265A4 (fr)	2014-11-19
PT3683209T (pt)	2021-12-15
PL2718265T3 (pl)	2016-04-29
AU2017202414A1 (en)	2017-05-04
CA2838194C (fr)	2022-01-11
CY1122639T1 (el)	2021-03-12
JP2021059573A (ja)	2021-04-15
HK1252109A1 (en)	2019-05-17
US11267785B2 (en)	2022-03-08
US20230002323A1 (en)	2023-01-05
HRP20151416T1 (hr)	2016-03-25
ES2771232T3 (es)	2020-07-06
US20170362178A1 (en)	2017-12-21
SI2718265T1 (sl)	2016-03-31
CA3135440A1 (fr)	2012-12-13
PT3290404T (pt)	2020-02-19
RU2764667C2 (ru)	2022-01-19
LT3683209T (lt)	2022-01-10
MX347709B (es)	2017-05-10
PL3683209T3 (pl)	2022-02-21
DK3000808T3 (da)	2017-11-27
EP4026829A1 (fr)	2022-07-13
HK1196616A1 (zh)	2014-12-19
JP2019123741A (ja)	2019-07-25
IL229775A (en)	2016-06-30
HUE057571T2 (hu)	2022-05-28
SI3290404T1 (sl)	2020-03-31
KR102293016B1 (ko)	2021-08-26
DK3290404T3 (da)	2020-02-17
AU2012268426A1 (en)	2014-01-09
DK2718265T3 (en)	2016-01-25
HRP20200197T1 (hr)	2020-05-15
EP2718265A1 (fr)	2014-04-16
KR20190141805A (ko)	2019-12-24
CY1119605T1 (el)	2018-04-04
US10246416B2 (en)	2019-04-02
EP3000808A1 (fr)	2016-03-30
JP7039682B2 (ja)	2022-03-22
PL3000808T3 (pl)	2018-03-30
RU2013158640A (ru)	2015-07-20
US20120309977A1 (en)	2012-12-06
ES2559850T3 (es)	2016-02-16
CY1124874T1 (el)	2022-11-25
KR102171315B1 (ko)	2020-10-28
AU2018250355A1 (en)	2018-11-08
AU2017202414B2 (en)	2018-07-19
US20210122715A1 (en)	2021-04-29
JP2022081597A (ja)	2022-05-31
EP3290404B1 (fr)	2019-12-11
HK1216173A1 (en)	2016-10-21
SI3683209T1 (sl)	2022-03-31
RU2016139352A (ru)	2018-12-13
HUE026096T2 (en)	2016-05-30
CA2838194A1 (fr)	2012-12-13

Publication	Publication Date	Title
BR112013031251A2 (fr)	2017-09-12
BR112013027245A2 (fr)	2017-01-03
BR112013026905A2 (fr)	2017-01-03
BR112013017670A2 (fr)	2017-08-15
BR112013027830A2 (fr)	2017-01-03
AP3853A (fr)	2016-09-30
BR112013027452A2 (fr)	2017-01-03
BR112013028733A2 (fr)	2017-08-29
BR112013027121A2 (fr)	2017-01-03
AP2016009466A0 (fr)	2016-09-30
BR112013031556A2 (fr)	2017-08-29
BR112013032368A2 (fr)	2017-01-03
NO2686520T3 (fr)	2018-03-17
BR112013032377A2 (fr)	2017-01-03
BR112013032380A2 (fr)	2017-01-03
BR112013027836A2 (fr)	2017-01-03
BR112013026895A2 (fr)	2017-01-03
BR112013027761A2 (fr)	2017-01-03
BR112013032392A2 (fr)	2017-01-03
BR112013030734A2 (fr)	2017-04-04
BR112013027871A2 (fr)	2017-01-03
BR112013032394A2 (fr)	2017-01-03
BR112013027112A2 (fr)	2017-01-03
BR112013027657A2 (fr)	2017-01-03
AP3777A (fr)	2016-08-31